Seribantumab (INN; development code MM-121) is a monoclonal antibody designed for the treatment of cancer. It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor.

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.